PharVision Advisers’s Quest Diagnostics DGX Stock Holding History

PharVision Advisers’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,386	Closed	-$241K	–	251
2025 Q4	$241K	Buy	+1,386	New	+$252K	0.12%	422

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

PharVision Advisers's DGX Position: Q1 2026 in Review

PharVision Advisers sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,386 shares — an estimated $241K sold.

PharVision Advisers first reported a position in DGX in Q4 2025 and held it in 1 quarter. The position peaked at $241K in Q4 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

PharVision Advisers reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,386 Quest Diagnostics shares in Q1 2026, an estimated $241K.
PharVision Advisers first reported a position in Quest Diagnostics in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Quest Diagnostics position peaked at $241K in Q4 2025.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.